Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children – A randomized controlled trial

@inproceedings{SezLlorens2017EfficacyO1,
  title={Efficacy of 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine against acute otitis media and nasopharyngeal carriage in Panamanian children – A randomized controlled trial},
  author={Xavier S{\'a}ez-Llorens and Stella Rowley and Digna Wong and Mirna Rodr{\'i}guez and Arlene E. Calvo and Marisol Troiti{\~n}o and Albino Salas and Vielka Vega and Mar{\'i}a Mercedes Castrej{\'o}n and Patricia Lommel and Thierry G. Pascal and William P. Hausdorff and Dorota Borys and Javier Ruiz-Gui{\~n}az{\'u} and Eduardo Ortega-Barr{\'i}a and Juan Pablo Yarz{\'a}bal and Lode M Schuerman},
  booktitle={Human vaccines & immunotherapeutics},
  year={2017}
}
We previously reported 10-valent pneumococcal non-typeable Haemophilus influenzae (NTHi) protein D conjugate vaccine (PHiD-CV) efficacy in a double-blind randomized trial (ClinicalTrials.gov: NCT00466947) against various diseases, including acute otitis media (AOM). Here, we provide further analyses. In the Panamanian subset, 7,359 children were randomized… CONTINUE READING